Teva Pharmaceutical Industries Limited
TEVA
$15.38
-$0.07-0.45%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.07% | 3.82% | 4.40% | 9.81% | 8.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.07% | 3.82% | 4.40% | 9.81% | 8.47% |
| Cost of Revenue | 1.85% | 3.38% | 3.40% | 1.68% | 0.34% |
| Gross Profit | 2.31% | 4.29% | 5.48% | 19.43% | 18.25% |
| SG&A Expenses | 5.12% | 5.42% | 5.80% | 6.35% | 4.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 45.45% | 183.33% | -175.00% | -101.64% | -83.58% |
| Total Operating Expenses | 2.55% | 4.19% | 3.99% | 2.64% | 2.11% |
| Operating Income | 0.32% | 2.42% | 6.07% | 45.27% | 40.63% |
| Income Before Tax | 51.05% | 36.78% | -106.43% | 77.27% | 93.58% |
| Income Tax Expenses | -84.68% | 2,153.85% | 11,350.00% | 574.51% | 174.66% |
| Earnings from Continuing Operations | 78.27% | -68.80% | -218.02% | 49.90% | 69.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -98.32% | -88.78% | 471.43% | 180.43% | 206.19% |
| Net Income | 65.12% | -168.48% | -192.68% | 58.96% | 80.72% |
| EBIT | 0.32% | 2.42% | 6.07% | 45.27% | 40.63% |
| EBITDA | -1.01% | -0.20% | 2.28% | 27.27% | 23.09% |
| EPS Basic | 63.80% | -165.52% | -188.79% | 59.79% | 81.22% |
| Normalized Basic EPS | -14.71% | -10.17% | 29.93% | 86.62% | 81.07% |
| EPS Diluted | 60.64% | -161.53% | -181.76% | 59.09% | 80.58% |
| Normalized Diluted EPS | -14.69% | -9.83% | 31.09% | 86.42% | 80.19% |
| Average Basic Shares Outstanding | 1.18% | 1.16% | 1.01% | 0.96% | 0.92% |
| Average Diluted Shares Outstanding | 1.28% | 0.95% | 0.33% | 1.00% | 1.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |